Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 26;12:5135. doi: 10.1038/s41467-021-25479-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a Serum antibody levels (EC50) that recognize the spike RBD of the wild-type USA-WA1/2020 (WA1) (Blue circles), B.1.1.7 (Orange squares), and B.1.351 (Green triangles) variants are shown. The RBD-B.1.1.7 carries the N501Y mutation, the only RBD mutation present in the B.1.1.7 variant. The RBD-B.1.351 has the K417N, E484K, and N501Y mutations which are the only three RBD mutations present in the B.1.351 variant. n = 51 biologically independent samples. b Comparison of neutralization titers (FRNT50) between WA1, B.1.1.7 (P = 0.0351) and B.1.351 (P = 0.0089) for BNT162b2 vaccinee sera. n = 50 biologically independent samples. c Correlation of variant matched RBD-specific antibody levels and neutralization titers (FRNT50) of the WA1 virus and the two variants. d, e Correlations between neutralization titers of the B.1.1.7 (d) and B.1.351 (e) variants with the WA1 virus. The dotted diagonal lines indicate identical neutralization, and the solid diagonal black lines indicate 10-fold differences in neutralization. f–h Correlation between participant age and neutralization titer against WA1 (f) (P < 0.0001), B.1.1.7 (g) (P < 0.0001), and B.1.351 (h) (P < 0.0001). n = 50 biologically independent samples. i Effect of age range 20–50 years (blue triangle) and >50 years (red inverted triangle) on the neutralization potency among the BNT162b2 vaccine recipients (WA1,B.1.1.7 P < 0.0001, B.1.351 P = 0.0001). n = 25 biologically independent samples per age group. For a, b, f–i, data are presented as the mean ± SD of log transformed values; P values are two-sided and include a Šidák multiple comparison correction. All experiments were performed in duplicate.

HHS Vulnerability Disclosure